Literature DB >> 6143602

Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats.

E L Schiffrin, J Gutkowska, G Thibault, J Genest.   

Abstract

The angiotensin I converting enzyme (ACE) inhibitor enalapril (MK-421), at a dose of 1 mg/kg or more by gavage twice daily, effectively inhibited the pressor response to angiotensin I for more than 12 h and less than 24 h. Plasma renin activity (PRA) did not change after 2 or 4 days of treatment at 1 mg/kg twice daily despite effective ACE inhibition, whereas it rose significantly at 10 mg/kg twice daily. Blood pressure fell significantly and heart rate increased in rats treated with 10 mg/kg of enalapril twice daily, a response which was abolished by concomitant angiotensin II infusion. However, infusion of angiotensin II did not prevent the rise in plasma renin. Enalapril treatment did not change urinary immunoreactive prostaglandin E2 (PGE2) excretion and indomethacin did not modify plasma renin activity of enalapril-treated rats. Propranolol significantly reduced the rise in plasma renin in rats receiving enalapril. None of these findings could be explained by changes in the ratio of active and inactive renin. Water diuresis, without natriuresis and with a decrease in potassium urinary excretion, occurred with the higher dose of enalapril. Enalapril did not potentiate the elevation of PRA in two-kidney one-clip Goldblatt hypertensive rats. In conclusion, enalapril produced renin secretion, which was in part beta-adrenergically mediated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143602     DOI: 10.1139/y84-019

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  5 in total

1.  The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs.

Authors:  D Cambridge; M V Whiting; L J Butterfield; G Allan
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 2.  Preclinical studies on angiotensin converting enzyme inhibitors.

Authors:  I L Natoff
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 3.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 4.  Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.

Authors:  K Chatterjee; T De Marco
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  Placental insufficiency results in temporal alterations in the renin angiotensin system in male hypertensive growth restricted offspring.

Authors:  Daniela Grigore; Norma B Ojeda; Elliot B Robertson; Antoinette S Dawson; Contrina A Huffman; Erick A Bourassa; Robert C Speth; K Bridget Brosnihan; Barbara T Alexander
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-05-30       Impact factor: 3.619

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.